Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial.
Rolf WachterSanjiv J ShahMartin R CowiePeter SzecsödyVictor ShiGhionul IbramZiqiang ZhaoJianjian GongSven KlebsBurkert PieskePublished in: ESC heart failure (2020)
PARALLAX will determine if sacubitril/valsartan compared with standard medical therapy for co-morbidities improves NT-proBNP levels, exercise capacity, quality of life, and symptom burden in HF patients with EF >40%.